London, England, April 4, 2012 

Ceva was very proud to support the 8th International Symposium on Avian Influenza organized by the Animal Health and Veterinary Laboratories Agency UK. Hosted in the Royal Holloway, University of London, this important Congress welcomed 300 professionals working in related scientific fields around the world, including research, regulatory, and control of Avian Influenza.

The symposium was a unique opportunity to experience scientific presentations, exchange and discuss information, receive updated information on the current status of Avian Influenza, and learn innovative ways to control the disease.

Vectormune HVT-AIV is an innovative Avian Influenza vaccine that uses the latest vector vaccine technology to provide more reliable protection against the H5N1 virus. (Read the last Press Release on Vectormune HVT-AIV)

“Ceva and independent research centers have conducted several laboratory and field experiments with Vectormune HVT-AIV. The results reveal such outstanding potency features and flexibility that we believe this vaccine can dramatically help in improving the control of Avian Influenza,” said Yannick Gardin, Director of Innovation Strategy at Ceva Santé Animale.

Ceva actively participated in the scientific program with presentations of two oral and three poster papers by both external and internal scientists. The company also used the symposium to launch a comprehensive guide containing all scientific information on Vectormune HVT-AIV.

More information is also available upon request.